Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
Exploration and evaluation of strategic alternatives continueWESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) — Portage Biotech Inc. (“Portage” or the…
Pharmaceuticals, Biotechnology and Life Sciences
Exploration and evaluation of strategic alternatives continueWESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) — Portage Biotech Inc. (“Portage” or the…
SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical…
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused…
SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing…
TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that…
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant,…
Webcast planned for Monday, November 25th at 8:00 AM ETAUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc.…
– Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been…
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) — BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James…